AIM: To observe clinical effect of vitrectomy with intravitreal ranibizumab for the treatment of diabetic retinopathy(DR).

METHODS: From February 2011 to February 2013, there were 90 cases in our hospital diabetic retinopathy patients withvitrectomy surgery. It was randomly divided into observation group(45 cases)and control group(45 cases). Two groups of patients were performed vitrectomy. Patients in observation group were injected intravitreal ranibizumab before surgery, then vitrectomy was underwent for diabetic retinopathy. Vitrectomy was only underwent in control group.

RESULTS: The patients in observation group with good effect accounting for 71%(32/45)and good rate was 89%(40/45), which were significantly higher than that in control group 51%(23/45), 71%(32/45). Differences were statistically significant(P<0.05). Amount of bleeding was 9.64±2.27mL, intraocular pressure was 13.64±3.27mmHg. It was significantly less than that in control group 10.21±3.14mL, 16.00±3.14mmHg. Differences were statistically significant(P<0.05).

CONCLUSION: The vitrectomy with intravitreal ranibizumab treatment of diabetic retinopathy can not only reduce blood loss, but also reduce edema and improve effectiveness and safety. It's worth recommending for clinical practice.